BioMarin and Dr Reddy's reach settlement over Kuvan tablets litigation

21 September 2015

US biotech company BioMarin Pharmaceuticals (Nasdaq: BMRN) and Indian pharma company Dr Reddy’s Laboratories (NYSE: RDY) have settled their patent litigation over Kuvan (sapropterin) tablets.

BioMarin will allow Dr Reddy’s to market a generic version of Kuvan, a treatment for phenylketonuria, in the USA at some time in the future. Dr Reddy’s will be granted a non-exclusive license to patents related to Kuvan with its generic set to launch "beginning at a confidential date in the future, but which is more than five years from today, or earlier under certain circumstances."

Kuvan was approved in 2007 by the US Food and Drug Administration for patients with phenylketonuria, and was developed in partnership between BioMarin and Merck Serono.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK